Clinical benefits of treatment with SQ house dust mite sublingual tablet in house dust mite allergic rhinitis.
Where this comes from
- Record sourced from PubMed, PMID 28273339.
- Also identified by DOI 10.1111/all.13155.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Treatment with SQ (standardised quality) house dust mite sublingual tablet for 1 year resulted in a decreased probability of having an allergic rhinitis (AR) exacerbation day (from 11% [placebo] to 5% [SQ house dust mite sublingual tablet]) and an increased probability of having a mild AR day (from 16% [placebo] to 34% [SQ house dust mite sublingual tablet]).
Medical subject headings
- Allergens
- Antigens, Dermatophagoides
- Pyroglyphidae
- Rhinitis, Allergic
- Sublingual Immunotherapy